Cavapro 75 mg (Tablet)
Unit Price: ৳ 6.00 (3 x 10: ৳ 180.00)
Strip Price: ৳ 60.00
Medicine Details
Category | Details |
---|---|
Generic | Irbesartan |
Company | Unimed unihealth pharmaceuticals ltd |
Also available as |
Indications
- Treatment of essential hypertension
- Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus
Pharmacology
- Angiotensin II receptor antagonist
- Blocks vasoconstricting effects of angiotensin II
- Blocks aldosterone-secreting effects by binding to AT1 receptors
Dosage & Administration
- Usual recommended initial dose: Irbesartan 150 mg once daily
- Maintenance dose: Irbesartan 150 mg once daily, with or without food
- Better 24 hour blood pressure control with 150 mg than 75 mg
- Consider initiation with Irbesartan 75 mg in haemodialysed patients and elderly over 75 years
- Dose can be increased to Irbesartan 300 mg if insufficiently controlled with 150 mg
Interaction
- Risk of hypotension when initiating therapy with diuretics and other antihypertensive agents
- Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium not recommended
- Potential reversible increases in serum lithium concentrations and toxicity with concomitant administration of lithium
- Attenuation of antihypertensive effect when administered with non-steroidal anti-inflammatory drugs
Contraindications
- Concomitant use with aliskiren in patients with diabetes and renal impairment (GFR <60 ml/min)
- Pregnancy
Side Effects
- Diarrhoea
- Fatigue
- Dyspepsia or heartburn
- Dizziness
- Orthostatic hypotension
- Nausea
- Vomiting
- Musculoskeletal pain
- Thrombocytopaenia
- Hyperkalaemia
- Elevated serum creatinine
Pregnancy & Lactation
- Contraindicated in second and third trimesters of pregnancy
- Avoid use during first trimester of pregnancy
- Contraindicated during lactation
- Not known whether excreted in human milk
Precautions & Warnings
- Patients with unilateral or bilateral renal artery stenosis
- Patients with depletion of intravascular volume
- Patients with aortic or mitral stenosis
- Patients with obstructive hypertrophic cardiomyopathy
- Patients with renal impairment
- Patients with hepatic impairment
- Close monitoring of serum potassium in patients at risk
Use in Special Populations
- No dosage adjustment necessary in patients with impaired renal function
- Lower starting dose in patients undergoing haemodialysis
- No dosage adjustment necessary in patients with mild to moderate hepatic impairment
- Effects on renal and cardiovascular events not uniform across all subgroups in patients with advanced renal disease
- Close monitoring of serum potassium in patients at risk
- Special caution in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy
- Not recommended for patients with primary aldosteronism
- Association with acute hypotension in patients whose vascular tone and renal function depend predominantly on the renin-angiotensin-aldosterone system
Overdose Effects
- No toxicity observed in adults exposed to doses of up to 900 mg/day for 8 weeks
- Expected manifestations of overdosage: hypotension, tachycardia, bradycardia
- No specific information available on treatment of overdosage with Cavapro
- Symptomatic and supportive treatment suggested
- Activated charcoal may be useful in treatment of overdosage
- Not removed by haemodialysis
Therapeutic Class
- Angiotensin-II receptor blocker
Storage Conditions
- Store in a cool and dry place
- Protected from light